|Day Low/High||10.73 / 10.91|
|52 Wk Low/High||4.88 / 12.04|
We made several trades and price target changes during a mixed week for the portfolio.
The portfolio has some high fliers and underperformers last week as we head into the heart of earnings season.
We brought a new name into the portfolio last week as the Fed's comments helped lift the market.
We made no trades during the holiday-shortened week, but added to our natural hedge today.
Check these names out.
From bank stocks to tech, these are my favorite names.
We added a name to the portfolio's Bullpen as a whirlwind quarter came to an end.
Enzo Biochem Inc. (NYSE:ENZ) reported today that a federal judge for the U.
We exited 2 positions and took some profits during a busy week for the portfolio.
We'll sell half of our ENZ position on today's strength.
We'll exit our tiny stake in AIRI, and look to take some profits in ENZ.
We're adding to PXLW, raising our target on ENZ, and prepared to buy more AXAS on weakness.
We initiated a new position and made several other trades during a week of twists and turns.
We'll initiate a small position in Air Industries Group. Plus, an update on Enzo Biochem.
We initiated 2 new positions in a week dominated by political events.
Enzo Biochem Inc. (NYSE:ENZ) today announced growth in operating results for the third fiscal quarter and nine months ended April 30, 2017.
Enzo Biochem, Inc. (NYSE:ENZ) today announced that the New York State Department of Health has granted conditional approval for three additional women's health related molecular diagnostic tests for use with the Company's...
We scaled further into one position and added a Bullpen name as the market shrugged off geopolitical uncertainties.
Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss fiscal 2017 third quarter results, Friday, June 9, 2017, at 8:30 AM E.
It was a busy week of moves in the portfolio as we head into the latter half of the second quarter.
Big moves for both stocks mean we need to modify our positions.
We initiated one new position and exited another last week, while several other names reported earnings.
Investors considering a purchase of Enzo Biochem, Inc. stock, but tentative about paying the going market price of $8.69/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Enzo Biochem, Inc. (NYSE:ENZ) announced today that its Enzo Clinical Laboratory subsidiary, a full-service clinical laboratory with a specialty in women's health, today reached an agreement with the nation's fourth largest...
Enzo Biochem, Inc. (NYSE:ENZ) today reported continued strong growth in operating results for the fiscal quarter and six months ended January 31, 2017.
Enzo Biochem, Inc. (NYSE:ENZ), has rescheduled its planned conference call to discuss fiscal 2017 second quarter results for this afternoon, Monday, March 13, 2017, at 4:30 PM E.